# Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

> **NCT01559116** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 219 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** tiotropium + olodaterol
- **DRUG:** tiotropium
- **DRUG:** olodaterol
- **DRUG:** tiotropium
- **DRUG:** tiotropium + olodaterol
- **DRUG:** Placebo
- **DEVICE:** Respimat

## Key facts

- **NCT ID:** NCT01559116
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2015-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01559116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01559116, "Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01559116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*